<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="143079">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02109484</url>
  </required_header>
  <id_info>
    <org_study_id>VAC-013</org_study_id>
    <nct_id>NCT02109484</nct_id>
  </id_info>
  <brief_title>Phase I/II Descending Age Study of P2VP8 Subunit Parenteral Rotavirus Vaccine in Healthy Toddlers and Infants</brief_title>
  <official_title>Phase I/II Descending Age Double-blinded Randomized Placebo-controlled Dose Escalation Study to Examine the Safety Reactogenicity Tolerability &amp; Immunogenicity of the P2-VP8 Subunit Parenteral Rotavirus Vaccine in Healthy Toddlers &amp; Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PATH</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>South Africa: Medicines Control Council</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is is a study of a parenteral rotavirus vaccine (P2-VP8 subunit rotavirus vaccine).
      The study will examine the safety and immunogenicity of this vaccine first in healthy South
      African toddlers.  If the safety profile is deemed appropriate, the study will continue to
      explore the safety and immunogenicity of the vaccine in healthy South African infants.

      The primary safety hypothesis is that the P2-VP8 subunit rotavirus vaccine is safe and
      well-tolerated in healthy toddlers and infants.  The primary immunogenicity hypothesis is
      that the P2-VP8 subunit rotavirus vaccine is immunogenic in infant participants and will
      induce an immune response in at least 80% of participants in at least one of the study
      groups.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>number of vaccine induced reactions</measure>
    <time_frame>7 days following each dose</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>local and systemic reactogenicity events will be monitored for a week following each dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>proportion of infants with anti-p2-vp8 IgG and IgA sero responses</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>seroresponse is defined as a 4-fold increase in antibody titers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>number of adverse events</measure>
    <time_frame>6 mo following first vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>all adverse events will be recorded over the duration of the 6 month follow up period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>proportion of infants with anti-p2-vp8 IgG and IgA sero responses</measure>
    <time_frame>4 weeks post 3rd vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>seroresponse is defined as a 4 fold increase in antibody titer between baseline and 4 weeks post vaccination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibody GMT in infants before and after Rotarix vaccination</measure>
    <time_frame>day 84 and day 224</time_frame>
    <safety_issue>No</safety_issue>
    <description>exploratory endpoint looking at the  shedding of Rotarix among infants who are vaccinated with P2-VP8 subunit vaccine followed by Rotarix compared to those who received placebo followed by Rotarix.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>proportion of toddlers with anti P2-VP8 IgG and IgA seroresponses</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>seroresponse is defined as a 4-fold increase in antibody titer between baseline and 4 weeks following the 3rd vaccination</description>
  </other_outcome>
  <other_outcome>
    <measure>proportion of toddlers with an anti P2VP8 IgG and IgA seroresponses</measure>
    <time_frame>4 weeks post 3rd vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>seroresponse is defined as a 4 fold increase in antibody titer between baseline and 4 weeks post vaccination</description>
  </other_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Evaluation of a Rotavirus Vaccine</condition>
  <arm_group>
    <arm_group_label>Cohort A P2VP8 30mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A toddlers (24-35 mo) receiving P2VP8 Subunit Vaccine (30mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A Placebo dose level 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort A toddlers (24-35 mo); placebo for dose level 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A  P2VP8 60mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A toddlers (24-35 mo) receiving P2VP8 Subunit Vaccine (60mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A Placebo dose level 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort A toddlers (24-35 mo); placebo for dose level 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B1 P2VP8 10mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort B1 infants receiving P2VP8 Subunit Vaccine (10mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B1  placebo dose level 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort B1 infants; placebo for dose level 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B1 P2VP8 30mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort B1 receiving P2VP8 Subunit Vaccine (30mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B1 placebo dose level 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort B1 infants; placebo for dose level 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B1 P2VP8 60mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort B1 receiving P2VP8 Subunit Vaccine (60mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B1 placebo dose level 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort B1 infants; placebo for dose level 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B2  P2VP8 D1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort B2 infants P2VP8 second highest tolerated dose from Cohort B1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B2 P2VP8 D2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort B2 infants P2VP8 at highest tolerated dose from Cohort B1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B2 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort B2 infants Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A P2VP8 10mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A toddlers (24-35 mo) receiving P2VP8 Subunit Vaccine (10mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A Placebo dose level 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort A toddlers (24-35 mo); placebo for dose level 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>P2VP8 Subunit Vaccine 10mcg</intervention_name>
    <description>10 mcg</description>
    <arm_group_label>Cohort B1 P2VP8 10mcg</arm_group_label>
    <arm_group_label>Cohort A P2VP8 10mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>P2VP8 Subunit Vaccine 30 mcg</intervention_name>
    <description>30 mcg</description>
    <arm_group_label>Cohort A P2VP8 30mcg</arm_group_label>
    <arm_group_label>Cohort B1 P2VP8 30mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>P2VP8 Subunit Vaccine 60mcg</intervention_name>
    <description>60 mcg</description>
    <arm_group_label>Cohort A  P2VP8 60mcg</arm_group_label>
    <arm_group_label>Cohort B1 P2VP8 60mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cohort A Placebo dose level 2</arm_group_label>
    <arm_group_label>Cohort A Placebo dose level 3</arm_group_label>
    <arm_group_label>Cohort B1  placebo dose level 1</arm_group_label>
    <arm_group_label>Cohort B1 placebo dose level 1</arm_group_label>
    <arm_group_label>Cohort B1 placebo dose level 3</arm_group_label>
    <arm_group_label>Cohort B2 Placebo</arm_group_label>
    <arm_group_label>Cohort A Placebo dose level 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cohort B2 P2VP8 D1</intervention_name>
    <description>second highest tolerated dose from Cohort B1</description>
    <arm_group_label>Cohort B2  P2VP8 D1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cohort B2 P2VP8 D2</intervention_name>
    <description>Highest tolerated dose from Cohort B1</description>
    <arm_group_label>Cohort B2 P2VP8 D2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy infants/toddlers as established by medical history and clinical examination
             before entering study

          -  age:

               -  toddler cohort: &gt; or = 2 and &lt;3 years old at the time of enrollment

               -  infant cohort: &gt; or = 6 and &lt;8 weeks at the time of enrollment

          -  parental ability and willingness to provide informed consent

          -  parental intention to remain in the area with the child during the study period.

        Exclusion Criteria:

          -  Presence of fever on the day of enrollment

          -  Acute disease at the time of enrollment

          -  Concurrent participation in another clinical trial throughout the entire timeframe
             for this study

          -  Presence of malnutrition or any systemic disorder (cardiovascular, pulmonary,
             hepatic, renal, gastrointestinal, hematological, endocrine, immunological,
             dermatological, neurological, cancer or autoimmune disease) as determined by medical
             history and/or physical examination that would compromise the participant's health or
             is likely to result in nonconformance to the protocol

          -  For infant cohort, history of premature birth (&lt;37 weeks gestation)

          -  History of congenital abdominal disorders, intussusception, or abdominal surgery

          -  Known or suspected impairment of immunological function based on medical history and
             physical examination

          -  For infant cohort only, prior receipt of rotavirus vaccine

          -  A known sensitivity or allergy to any components of the study vaccine

          -  History of anaphylactic reaction

          -  Major congenital or genetic defect

          -  Participant's parents not able, available or willing to accept active weekly
             follow-up by the study staff

          -  Has received any immunoglobulin therapy and/or blood products since birth or planned
             administration during the study period

          -  History of chronic administration (defined as more than 14 days) of immunosuppressant
             medications, including corticosteroids. Infants on inhaled or topical steroids may be
             permitted to participate in the study

          -  Any medical condition in the parents/infant that, in the judgment of the
             investigator, would interfere with or serves as a contraindication to protocol
             adherence or a participant's parents' ability to give informed consent

          -  HIV infection

               -  For toddlers, to be assessed by HIV ELISA

               -  For infants, to be assessed by PCR, if mother is not known to be negative
                  (negative test result between 24 weeks gestation and screening)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>35 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Respiratory and Meningeal Pathogens Research Unit (RMPRU)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Groome, MBBCh</last_name>
      <phone>+27 11 983 4283</phone>
      <email>groomem@rmpru.co.za</email>
    </contact>
    <investigator>
      <last_name>Michelle Groome, MBBCh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 7, 2014</lastchanged_date>
  <firstreceived_date>April 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
